TL;DR: Pharmacy spend is one of the fastest-rising parts of employer health costs, and chronic conditions are a main reason. A better strategy uses condition-specific formularies, lower-cost generics and biosimilars, disease management, and Adherence support to lower waste while improving care.
Key Takeaways
- Chronic conditions such as diabetes, hypertension, asthma, and obesity drive a large share of pharmacy and medical spend.
- Employers heading into 2026 face rising health benefit costs, and pharmacy often accounts for about one quarter of total spend.
- GLP-1 drugs and specialty medications can move the budget fast, even when only a small share of members use them.
- Condition-specific formularies can guide members to high-value treatment options, including generics and biosimilars.
- Disease management and medication Adherence support can produce meaningful savings, often cited in the 15% to 20% range, depending on design and engagement.
- A 2025 benchmark cited in employer reporting found that about 50% of employers were using analytics to monitor Adherence.
The strongest pharmacy strategy reduces waste and improves health at the same time.
Pharmacy costs now shape benefit strategy in a bigger way than many employers expected. Chronic conditions sit at the center of that pressure, and the impact reaches far beyond the claims file.
For C-suite, HR, and finance leaders, the goal is better cost control without making treatment harder to reach. That takes a long-Term view, measurable outcomes, and a clear link between plan decisions and the people who rely on them.
What is driving pharmacy costs higher for chronic conditions? #
Several forces are hitting at once. First, chronic disease still drives most health spending in the United States. Second, drug mix is changing. Many employers now pay for more specialty drugs, and those drugs carry much higher price tags than common maintenance medications.
Pharmacy trend estimates for 2026 often fall in the 6.5% to 10%+ range, based on employer and pharmacy trend reporting. At the same time, specialty drugs make up a small share of prescriptions but a very large share of spend. That matters because cardiometabolic conditions, such as diabetes, obesity, hypertension, and heart disease, are common across working-age populations.
Mercer has also flagged GLP-1 cost management as a top issue for 2026. KFF has reported similar concern among large employers, especially when weight-loss coverage is included.
Why a few high-cost drugs can reshape the whole plan #
A handful of drugs can change the entire budget. GLP-1 medications are the clearest example. In employer cost discussions, these drugs have often landed around $1,000 to $1,300 per month per user, especially before rebates and Plan Design changes.
That number adds up fast. If 100 members use one of these drugs long-Term, annual gross spend can reach seven figures. Even when newer cash-pay offers lower the direct retail price for some buyers, employer-sponsored coverage still faces major exposure because plan costs depend on utilization, duration, and clinical rules.
KFF reporting has shown that many large firms saw a moderate or significant jump in drug spending after adding GLP-1 coverage for weight loss. So, this is not an isolated issue. It is a broad employer budget issue.
How poor Adherence turns pharmacy waste into bigger medical claims #
It is easy to focus on drug cost alone. That view misses the bigger picture.
When employees skip blood pressure medicine, stretch asthma inhalers, or stop diabetes treatment, the short-Term pharmacy savings often come back as higher medical claims. More Urgent Care visits, more ER use, and more avoidable complications follow. Absence and lost work time often rise too.
That is why the smarter metric is total cost of care, not pharmacy spend in isolation. A lower-cost script that no one takes is not a win. A well-matched medication that keeps someone out of the hospital usually is.
Build a chronic condition pharmacy strategy that lowers cost and supports care #
A strong pharmacy strategy starts with matching Plan Design to real condition needs. In plain English, that means the Formulary, member support, and communication should work together.
Too many employers still rely on broad controls that treat every prescription category the same. Chronic conditions do not work that way. Diabetes, hypertension, and asthma each have different Adherence risks, treatment patterns, and cost drivers.
Use condition-specific formularies to steer members to lower-cost, high-value drugs #
A condition-specific Formulary gives preferred coverage to the drugs that make the most clinical and financial sense for a given condition. For example, a plan might place proven first-line diabetes generics on the lowest cost tier while using tighter controls for high-cost options that are not the right first step.
This approach does not block access. It guides access. Members can still reach needed treatment, but the plan nudges them toward effective, lower-cost choices first.
Tiered coverage is a big part of this. Lower copays for preferred maintenance drugs, smart prior authorization rules, and clinically guided Step Therapy can all reduce avoidable spend. However, those decisions need strong claims review behind them. Good design starts with customizable claims analysis that shows where cost, use, and clinical gaps overlap.
Expand use of generics and biosimilars where they make clinical and financial sense #
Generics are chemical copies of brand drugs. Biosimilars are highly similar versions of biologic drugs, which are more complex medicines often used for conditions such as autoimmune disease or cancer.
Both can lower cost without lowering quality when the match is right. That is why many employers are reviewing PBM terms, Rebate structures, and Formulary placement more closely. A plan cannot capture savings if lower-cost options sit behind poor pricing terms or weak member communication.
Biosimilar uptake has improved in some categories, yet adoption still varies. Recent market data shows strong share gains in oncology, while other categories move more slowly. PBM decisions, Provider habits, and member concerns all shape the pace. So, employers should stay balanced. Push where the evidence is strong, and review each class with care.
Pair Plan Design with disease management and Adherence support #
Formulary changes work better when people know how to use their benefits and stay on treatment. That is where disease management and Adherence support matter.
Some employer reporting has tied these programs to savings in the 15% to 20% range. That can happen, but savings are not automatic. They depend on program design, engagement, baseline risk, and how well the program fits the population.
How disease management programs help employees stay healthier #
Good disease management is practical. It includes coaching, targeted education, outreach after gaps in care, help finding primary care, and support for people who struggle with medication routines.
This matters most for common employer conditions. Diabetes, high blood pressure, asthma, and obesity all require day-to-day decisions. Employees often need reminders, simple education, or help solving barriers such as cost, confusion, or side effects.
That is also why communication matters. People do not use benefits they do not understand. A thoughtful condition strategy should create informed healthcare consumers, not just lower line-item spend. Employers building this kind of support often benefit from custom population health strategies that connect outreach, education, and measurement.
What good Adherence incentives look like in the real world #
The best Adherence incentives remove friction. They do not punish people.
A plan might lower copays for high-value maintenance drugs, send refill reminders before a gap occurs, offer Care Navigation for people with several prescriptions, or reward evidence-based actions such as annual diabetic eye exams or regular controller use for asthma.
A 2025 employer benchmark cited in pharmacy trend discussions found that about half of employers were using analytics to monitor Adherence. Public 2026 benchmarks are still limited, but the direction is clear. More employers want data-guided oversight because it helps them target outreach where it matters most.
Employers can also learn from condition-focused education efforts. For example, JA has shared ideas on inclusive diabetes education programs that make support easier to access and easier to trust.
Use pharmacy analytics to find waste, measure progress, and guide next steps #
Raw spreadsheet data rarely leads to good decisions on its own. Leaders need insight that is easy to read and easy to act on.
Pharmacy analytics can show where nonadherence is rising, which drug classes drive trend, where generic or biosimilar use is low, and which chronic conditions carry the most cost. That matters to HR because member experience is at stake. It matters to finance because budget accuracy is at stake. It matters to executive leadership because benefit strategy affects retention, productivity, and long-Term ROR (Return on Relationship).
The pharmacy metrics leaders should watch every quarter #
These metrics give a useful starting point:
| Metric | Why it matters |
|---|---|
| Trend by condition | Shows which chronic diseases drive spend growth |
| Top drug classes | Identifies where plan dollars concentrate |
| Specialty spend share | Flags exposure to very high-cost therapies |
| Generic dispensing rate | Shows whether low-cost options are being used |
| Biosimilar adoption | Highlights savings opportunity in biologic classes |
| Refill behavior | Helps detect nonadherence early |
| Avoidable utilization | Connects pharmacy gaps to ER or inpatient use |
| Total cost of care | Keeps focus on outcomes, not script cost alone |
The takeaway is simple. Watch fewer metrics, but watch them well.
How to turn data into action without overwhelming your team #
A practical process works best. Start by listening to business goals and member pain points. Then assess current plan performance, identify the biggest gaps, develop targeted changes, communicate them clearly, and review progress on a set schedule.
That sounds simple because it should be. Employers do not need more noise. They need a repeatable way to move from data to decisions.
For teams that want clearer benchmarks, the Insight Benchmark Survey offers a useful example of how comparative data can become easier to interpret and more useful for planning.
Pharmacy costs for chronic conditions will keep rising if employers only react after the renewal hits. Better control comes from guiding members to high-value drugs, supporting Adherence, and measuring what changes over time.
Start with the conditions driving the most spend. Align Plan Design with member support. Then track quantifiable outcomes with the same discipline you expect from any other business investment.
